Oral antibiotics lower mycophenolate mofetil drug exposure, possibly by interfering with the enterohepatic recirculation: A case series

Autor: Mirjam Simoons, Kishan A. T. Naipal, Huib deJong, Caroline M. denHoed, Brenda C. M. deWinter, Midas B. Mulder

Publikováno v: Pharmacology Research & Perspectives, Vol 11, Iss 3, Pp n/a-n/a (2023)

Abstract Mycophenolate mofetil has an important role as immunosuppressive agent in solid organ transplant recipients. Exposure to the active mycophenolic acid (MPA) can be monitored using therapeutic drug monitoring. We present three cases in which M

Externí odkaz: https://doaj.org/article/c0238f5d29d14a3cbb864962b2176610

Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer.

Autor: Kishan A T Naipal, Anja Raams, Serena T Bruens, Inger Brandsma, Nicole S Verkaik, Nicolaas G J Jaspers, Jan H J Hoeijmakers, Geert J L H van Leenders, Joris Pothof, Roland Kanaar, Joost Boormans, Dik C van Gent

Publikováno v: PLoS ONE, Vol 10, Iss 4, p e0126029 (2015)

Bladder cancer has a high incidence with significant morbidity and mortality. Attenuated expression of the DNA damage response protein Xeroderma Pigmentosum complementation group C (XPC) has been described in bladder cancer. XPC plays an essential ro

Externí odkaz: https://doaj.org/article/ea3f2b994d0f42af98b9ca103f83e8f6

Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladder

Autor: Joost L. Boormans, Nathalie van den Tempel, Martine Franckena, Roland Kanaar, Dik C. van Gent, Kishan A. T. Naipal, Anja Raams

Publikováno v: PLoS ONE, 13(12):0209101. PUBLIC LIBRARY SCIENCE
PLoS One (online), 13(12):e0209101. Public Library of Science
PLoS ONE
PLoS ONE, Vol 13, Iss 12, p e0209101 (2018)

IntroductionBladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical ad

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb99773740e1c78a39a626dd3b763a7a
https://research.rug.nl/en/publications/340dec62-e42b-4d75-9c99-bb499c9bea5d

Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment

Autor: Roland Kanaar, Mark J. O'Connor, Carolien H.M. van Deurzen, Agnes Jager, Harry Vrieling, Dik C. van Gent, Matty Meijers, John W.M. Martens, Anieta M. Sieuwerts, Maaike P.G. Vreeswijk, Kishan A. T. Naipal, Jan H.J. Hoeijmakers, Johan P. de Winter, Nicole S. Verkaik, Petra ter Brugge, Najim Ameziane, Jos Jonkers

Publikováno v: Naipal, K A T, Verkaik, N S, Ameziane, N, van Deurzen, C H M, ter Brugge, P, Meijers, M, Sieuwerts, A M, Martens, J W, O'Connor, M J, Vrieling, H, Hoeijmakers, J H J, Jonkers, J, Kanaar, R, de Winter, J P, Vreeswijk, M P, Jager, A & van Gent, D C 2014, ' Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment ', Clinical Cancer Research, vol. 20, no. 18, pp. 4816-4826 . https://doi.org/10.1158/1078-0432.CCR-14-0571
Clinical Cancer Research, 20(18), 4816-4826. American Association for Cancer Research Inc.
Clinical Cancer Research, 20(18), 4816-4826

Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e4f8dc88513988357a12f8fdb2d13b9
https://doi.org/10.1158/1078-0432.ccr-14-0571

Abstract 3392: Ex vivo analysis of RAD51 foci induction in fresh tumor tissue: a promising new tool for the identification of homologous recombination-deficient tumors

Autor: D.C. van Gent, Jan H.J. Hoeijmakers, Roland Kanaar, Maaike P.G. Vreeswijk, Matty Meijers, Agnes Jager, Katja N. Gaarenstroom, Harry Vrieling, Kishan A. T. Naipal, Vthbm Smit, Nicole S. Verkaik

Publikováno v: Cancer Research. 75:3392-3392

Purpose. BRCA1 and BRCA2 related breast and ovarian tumors respond very well to treatment with PARP inhibitors (PARPi) because of their deficiency in homologous recombination (HR). We have indications that a substantial number of ovarian tumors might

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be719529f1e3b69ce475a3d10adfa6d9
https://doi.org/10.1158/1538-7445.am2015-3392